Bristol-Myers Squibb To Present New Overall Survival Data For Opdivo (nivolumab) As Monotherapy And In Combination With Yervo (ipilimumab) At The AACR 2016 Annual Meeting

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that new clinical research data for two of its Immuno-Oncology medicines -- Opdivo and Yervoy -- will be presented at the American Association for Cancer Research (AACR) 2016 Annual Meeting in New Orleans, LA, from April 16-20.